DURECT Corporation ( (DRRX) ) has released its Q3 earnings. Here is a breakdown of the information DURECT Corporation presented to its investors.
DURECT Corporation is a late-stage biopharmaceutical company focused on developing epigenetic therapies aimed at treating serious and life-threatening conditions, including acute organ injury, primarily in the healthcare sector.
In the third quarter of 2024, DURECT Corporation reported financial results highlighting their preparation for a Phase 3 trial for larsucosterol, a potential treatment for severe alcohol-associated hepatitis (AH). The company aims to initiate this trial soon, given adequate funding, with the potential for FDA approval based on a single successful trial.
Key financial metrics for the quarter include total revenues of $1.9 million and a net loss of $4.3 million. The company’s cash position was $10.5 million as of September 30, 2024, a significant decrease from $29.8 million at the end of 2023, reflecting ongoing investments in research and development. Additionally, Innocoll Pharmaceuticals announced the termination of its license agreement for POSIMIR®, impacting DURECT’s commercialization strategy for this product.
Strategic announcements include the planned Phase 3 trial for larsucosterol, designed as a randomized, double-blind, placebo-controlled study. The upcoming trial incorporates feedback from the FDA and aims to demonstrate the drug’s efficacy in improving 90-day survival rates for AH patients.
Looking ahead, DURECT Corporation is focused on advancing the clinical development of larsucosterol, with management optimistic about its potential impact on treating AH. The company remains committed to securing the necessary funding to support these initiatives and improve its financial position.
